Evidence map›Paper›PMID 41355907›Full record

ReviewWorld journal of clinical oncology2025

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment.

Samarah Arjumand, Asef Raj, Kazi Milenur Rahman Prattay, Humair Bin Md Omer, Faruque Azam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samarah ArjumandSchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
Asef RajSchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
Kazi Milenur Rahman PrattaySchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
Humair Bin Md OmerSchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
Faruque AzamSchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy represents a major advance in cancer immunotherapy, offering targeted treatment options, particularly for hematologic malignancies. This review comprehensively explores the structural evolution, production processes, and cytotoxic mechanisms underlying CAR-T function. Therapy involves engineering autologous T cells with synthetic receptors that allow major histocompatibility complex-independent recognition of tumor-associated antigens. Key structural components such as antigen recognition domains, spacers, transmembrane, and intracellular domains are optimized to enhance specificity, persistence, and cytotoxicity. CAR-T therapy exerts antitumor effects

Indexed as

Cancer immunotherapyChimeric antigen receptorChimeric antigen receptor structureChimeric antigen receptor T clinical trialsImmunotherapy challengesT cell engineering

Identifiers

PMID41355907
PMCPMC12678908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.